Atara Biotherapeutics (ATRA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Atara Biotherapeutics, Inc. has announced the termination of its Executive Vice President, Chief Medical Officer’s employment, effective February 2, 2024, due to a workforce reduction. The outgoing executive, Dr. Joshi, will continue to provide services under a consulting agreement until January 31, 2025, earning a monthly fee of $3,000 plus additional hourly compensation. Dr. Joshi’s equity awards will also vest during this period, and he may receive a significant bonus upon FDA approval of a key biologics license application.
For further insights into ATRA stock, check out TipRanks’ Stock Analysis page.